Naturally occurring multipotent anti-Alzheimer's agents

Expert Opinion on Drug Discovery

Volumn 1, Issue 3, 2006, Pages 269-277

  Zhang, Hong Yu ^a   Yang, Da Peng ^a   Ji, Hong Fang ^a  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

acetylcholinesterase inhibitor; Alzheimer's disease; amyloid aggregation inhibitor; antioxidant; metal ion chelator; monoamine oxidase inhibitor

Indexed keywords

EID: 33750722002     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.3.269     Document Type: Review

References (73)

1. MATTSON MP: Pathways towards and away from Alzheimer's disease. Nature (2004) 430(7000):631-639.
2. CUMMINGS JL: Alzheimers disease. N. Engl. J. Med. (2004) 351(1):56-67.
3. BENSON A: Alzheimers disease: a tangled issue. Drug. Discov. Today (2005) 10(11):749-751.
4. BARNHAM KJ, MASTERS CL, BUSH AI: Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. (2004) 3(3):205-214.
5. BROWN DR, KOZLOWSKI H: Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases. Dalton Trans. (2004) (13):1907-1917.
6. CITRON M: Strategies for disease modification in Alzheimer's disease. Nat. Rev. Neurosci. (2004) 5(9):677-685.
7. THORSETT ED, LATIMER LH: Therapeutic approaches to Alzheimers disease. Curr. Opin. Chem. Biol. (2000) 4(4):377-382.
8. FORMAN MS, TROJANOWSKI JQ, LEE VM-Y: Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. (2004) 10(10):1055-1063.
9. HARDY J, ORR H: The genetics of neurodegenerative diseases. J. Neurochem. (2006) 97(6):1690-1699.
10. POPE SK, SHUE VM, BECK C: Will a healthy lifestyle help prevent Alzheimers disease? Ann. Rev. Public Health (2003) 24:111-132.
11. KADUSZKIEWICZ H, ZIMMERMANN T, BECK-BORNHOLDT HP et al.: Cholinesterase inhibitors for patients with Alzheimers disease: systematic review of randomised clinical trials. Br. Med. J. (2005) 331(7512):321-327.
12. MAGGINI M, VANACORE N, RASCHETTI R et al.: Cholinesterase inhibitors: drugs looking for a disease? PLoS Med. (2006) 3(4):e140.
13. KEITH CT, BORISY AA, STOCKWELL BR: Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. (2005) 4(1):71-78.
14. YOUDIIM MB, BUCCAFUSCO JJ: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. (2005) 26(1):27-35.
15. ZHANG H-Y: One-compound-multiple-targets strategy to combat Alzheimers disease. FEBS. Lett. (2005) 579(24):5260-5264.
16. MORPHY R, KAY C, RANKOVIC Z: From magic bullets to designed multiple ligands. Drug Discov. Today (2004) 9(15):641-651.
17. MORPHY R, RANKOVIC Z: Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. (2005) 48(21):6523-6543.
18. MENCHER SK, WANG LG: Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC. Clin. Pharmacol. (2005) 5(1):3.
19. SCARMEAS N, STERN Y, TANG M-X et al.: Mediterranean diet and risk for Alzheimer's disease. Ann. Neurol. (2006) 59(6):912-921.
20. TRUELSEN T, THUDIUM D, GRNBK M et al.: Amount and type of alcohol and risk of dementia: the Copenhagen city heart study. Neurology (2002) 59(9):1313-1319.
21. LINDSAY J, LAURIN D, VERREAULT R et al.: Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging. Am. J. Epidemiol. (2002) 156(5):445-453.
22. KURIYAMA S, HOZAWA A, OHMORI K et al.: Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project. Am. J. Clin. Nutr. (2006) 83(2):355-361.
23. LUCHSINGER JA, TANG M-X, SIDDIQUI M et al.: Alcohol intake and risk of dementia. J. Am. Geriatr. Soc. (2004) 52(4):540-546.
24. HOWES M-JR, PERRY NSL, HOUGHTON P: Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother. Res. (2003) 17(1):1-18.
25. DIAMOND BJ, JOHNSON SK, TORSNEY K et al.: Complementary and alternative medicines in the treatment of dementia. Drugs Aging (2003) 20(13):981-998.
26. RICE-EVANS CA, MILLER NJ, PAGANGA G.: Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. (1996) 20(7):933-956.
27. PIETTA P: Flavonoids as antioxidants. J. Nat. Prod. (2000) 63(7):1035-1042.
28. TANIGUCHI S, SUZUKI N, MASUDA M et al.: Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. (2005) 280(9):7614-7623.
29. PORAT Y, ABRAMOWITZ A, GAZIT E: Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. (2006) 67(1):27-37.
30. REZAI-ZADEH K, SHYTLE D, SUN N et al.: Green tea epigallocatechin-3- gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. (2005) 25(38):8807-8814.
31. OBREGON DF, REZAI-ZADEH K, BAI Y et al.: ADAM10 activation is required for green tea-EGGC-induced α-secretase cleavage of amyloid precursor protein. J. Biol. Chem. (2006) 281(24):16419-16427.
32. REZNICHENKO L, AMIT T, ZHENG H et al.: Reduction of iron-regulated amyloid precursor protein and α-amyloid peptide by (-)-epigallocatechin-3- gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J. Neurochem. (2006) 97(2):527-536.
33. COS P, YING L, CALOMME M et al.: Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers. J. Nat. Prod. (1998) 61(1):71-76.
34. KIM H, PARK BS, LEE KG et al.: Effects of naturally occurring compounds on fibril formation and oxidative stress of α-amyloid. J. Agric. Food. Chem. (2005) 53(22):8537-8541.
35. ONO K, YOSHIIKE Y, TAKASHIMA A et al.: Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. (2003) 87(1):172-181.
36. LEE MH, LIN RD, SHEN LY et al.: Monoamine oxidase B and free radical scavenging activities of natural flavonoids in Melastoma candidum. J. Agric. Food Chem. (2001) 49(11):5551-5555.
37. CHIMENTI F, COTTIGLIA F, BONSIGNORE L et al.: Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis and computational study. J. Nat. Prod. (2006) 69(6):945-949.
38. SALVI A, BRÜLMANN C, MIGLIAVACCA E et al.: Protein protection by antioxidants: development of a convenient assay and structure-activity relationships of natural polyphenols. Helv. Chim. Acta (2002) 85(3):867-881.
39. GREIG NH, UTSUKI T, INGRAM DK et al.: Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer α-amyloid peptide in rodent. Proc. Natl. Acad. Sci. USA (2005) 102(47):17213-17218.
40. JI H-F, ZHANG H-Y: Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimers disease. J. Mol. Struct. (Theochem.) (2006). (In Press).
41. HAY AE, AUMOND MC, MALLET S et al.: Antioxidant xanthones from Garcinia vieillardii. J. Nat. Prod. (2004) 67(4):707-709.
42. LEE BW, LEE JH, LEE ST et al.: Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. Bioorg. Med. Chem. Lett. (2005) 15(24):5548-5552.
43. GNERRE C, THULL U, GAILLARD P et al.: Natural and synthetic xanthones as monoamine oxidase inhibitors: biological assay and 3D-QSAR. Helv. Chim. Acta (2001) 84(3):552-570.
44. BRÜHLMANN C, MARSTON A, HOSTETTMANN K et al.: Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors. Chem. Biodivers. (2004) 1(6):819-829.
45. JI H-F, TANG G-Y, ZHANG H-Y: Theoretical elucidation on structure-activity relationships of antioxidant xanthones. QSAR Combin. Sci. (2005) 24(7):826-830.
46. YAMANSHITA N, TANEMURA H, KAWANISHI S: Mechanism of oxidative DNA damage induced by quercetin in the presence of Cu(II). Mutat. Res. (1999) 425(1):107-115.
47. SUGIHARA N, ARAKAWA T, OHNISHI M et al.: Anti- and pro-oxidative effects of flavonoids on metal-induced lipid hydroperoxide-dependent lipid peroxidation in cultured hepatocytes loaded with α-linolenic acid. Free Radic. Biol. Med. (1999) 27(11-12):1313-1323.
48. COLE GM., YANG F, LIM GP et al.: A rationale for curcuminoids for the prevention or treatment of Alzheimers disease. Curr. Med. Chem.-Imun. Endo. Metab. Agents (2003) 3(1):233-243.
49. LIM GP, CHU T, YANG F et al.: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. (2001) 21(21):8370-8377.
50. CHANDRA V, GANGULI M, PANDAV R et al.: Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study. Neurology (1998) 51(4):1000-1008.
51. EVANS DA, FUNKENSTEIN HH, ALBERT MS et al.: Prevalence of Alzheimers disease in a community population of older persons higher than previously reported. J. Am. Med. Assoc. (1989) 262(18):2551-2556.
52. FRAUTSCHY SA, HU W, KIM P et al.: Phenolic anti-inflammatory antioxidant reversal of A α-induced cognitive deficits and neuropathology. Neurobiol. Aging. (2001) 22(6):993-1005.
53. AISEN PS: Development of antiinflammatory therapy for Alzheimer's disease. Drug Develop. Res. (2002) 56(3):421-427.
54. ONO K, HASEGAWA K, NAIKI H et al.: Curcumin has potent anti-amyloidogenic effects for Alzheimer's α-amyloid fibrils in vitro. J. Neurosci. Res. (2004) 75(6):742-750.
55. YANG F, LIM GP, BEGUM AN et al.: Curcumin inhibits formation of amyloid - oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. (2005) 280(7):5892-5901.
56. BALASUBRAMANIAN K: Molecular orbital basis for yellow curry spice curcumins prevention of Alzheimers disease. J. Agric. Food Chem. (2006) 54(10):3512-3520.
57. BAUM L, NG A: Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimer Dis. (2004) 6(4):367-377.
58. BARIK A, MISHRA B, SHEN L et al.: Evaluation of new copper-curcumin complex as superoxide dismutase mimic and its free radical reactions. Free Radic. Biol. Med. (2005) 39(6):811-822.
59. SHEN L, ZHANG H-Y, JI H-F: A theoretical study on Cu(II)-chelating properties of curcumin and its implications for curcumin as a multipotent agent to combat Alzheimers disease. J. Mol. Struct. (Theochem.) (2005) 757(1-3):199-202.
60. WANG R, YAN H, TANG X-C: Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin. (2006) 27 (1):1-26.
61. ZHANG H-Y, YANG D-P, TANG G-Y: Multifunctional antioxidants: from screening to design. Drug. Discov. Today (2006) 11 (15-16): 749-754.
62. ANTUNES F, BARCLAY LR, INGOLD KU et al.: On the antioxidant activity of melatonin. Free Radic. Biol. Med. (1999) 26(1):117-128.
63. ZHANG H-Y: Structure-activity relationships and rational design strategies for radical-scavenging antioxidants. Curr. Comput.-Aided Drug Design (2005) 1(3):257-273.
64. Traditional Chinese medicine database (Chinese edition), Accelrys Inc., Beijing, (2005).
65. HOUGHTON PJ, REN Y, HOWES MJ: Acetylcholinesterase inhibitors from plants and fungi. Nat. Prod. Rep. (2006) 23(2):181-199.
66. LASHUEL HA, HARTLEY DM, BALAKHANEH D et al.: New class of inhibitors of amyloid-fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J. Biol. Chem. (2002) 277(45):42881-42890.
67. GILGUN-SHERKI Y, MELAMED E, OFFEN D: Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology (2001) 40(8):959-975.
68. AZZI A, DABIES KJ, KELLY F: Free radical biology-terminology and critical thinking. FEBS Lett. (2004) 558(1-3):3-6.
69. SCALBERT A, JOHNSON IT, SALTMARSH M: Polyphenols: antioxidants and beyond. Am. J. Clin. Nutr. (2005) 81(Suppl.):215S-217S.
70. HALLIWELL B, RAFTER J, JENNER A: Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? antioxidant or not? Am. J. Clin. Nutr. (2005) 81(Suppl.):268S-276S.
71. OREILLY JD, MALLET AI, MCANLIS GT et al.: Consumption of flavonoids in onions and black tea: lack of effect on F2-isoprostanes and autoantibodies to oxidized LDL in healthy humans. Am. J. Clin. Nutr. (2001) 73(6):1040-1044.
72. YOUDIM KA, SHUKITT-HALE B, JOSEPHY JA: Flavonoids and the brain: interactions at the blood-brain barrier and their physiological effects on the central nervous system. Free Radic. Biol. Med. (2004) 37(11):1683-1693.
73. XIE XS, YU J, YANG WY: Living cells as test tubes. Science (2006) 312(5771):228-230.